These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Elevated level of Galectin-1 in bronchoalveolar lavage of patients with idiopathic pulmonary fibrosis.
    Author: Bennett D, Bargagli E, Bianchi N, Landi C, Fossi A, Fui A, Sestini P, Refini RM, Rottoli P.
    Journal: Respir Physiol Neurobiol; 2020 Feb; 273():103323. PubMed ID: 31678459.
    Abstract:
    RATIONALE: Galectin-1 is a carbohydrate-binding protein involved in apoptosis, cell-proliferation and differentiation, implicated in T-cell homeostasis and survival. The aim of the present study was to determine concentrations of galectin-1 in BAL fluid from patients with IPF and other interstitial lung diseases in order to validate proteomic previous findings. METHODS: 36 IPF patients (16 females, mean age of 64.8 ± 8.9 years), 24 sarcoidosis patients (15 females, mean age of 56.3 ± 13.4), 7 interstitial lung diseases associated to systemic sclerosis (ILD-SSc) patients (5 females, mean age of 55.5 ± 16.4) and six healthy controls (4 females, mean age 47.8 ± 15.2) were included. Galectin-1 concentrations were determined in BAL samples by an ELISA assay. RESULTS: Galectin-1 concentrations were significantly higher in BAL of IPF patients than in sarcoidosis and ILD-SSc patients and healthy controls. In IPF patients, galectin-1 levels showed significant inverse correlations with DLCO%, KCO% and BAL lymphocyte percentages and a positive correlation with BAL macrophage percentages. Former IPF smokers had higher concentrations of this protein compared with non-smoker IPF patients. CONCLUSION: Galectin-1 was confirmed a protein of interest in idiopathic pulmonary fibrosis. Its BAL concentrations were higher in IPF patients than in controls and correlated with disease severity. Galectin-1 was suggested to have a role in the pathogenesis of IPF, principally through the ERK/MAPK pathway and the inhibition of galectin-1 is a potential therapeutic target worthy of research.
    [Abstract] [Full Text] [Related] [New Search]